Circulating mutant DNA to assess tumor dynamics

By F. Diehl, Kerstin Schmidt, M. Choti, K. Romans, Steven N. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, Steve Szabo and 3 more. Nature Medicine, 2008

2,328 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/8395d5298c6cc2f9f16cbeb4fb4a00cd512ec423

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Pantel
2. A. Bardelli
3. J. Reis-Filho
4. L. Diaz
5. D. Hoon
6. Raghu Kalluri
7. C. Alix‐Panabières
8. D. Hanahan

In Pathology and Forensic Medicine

1. A. Bardelli
2. K. Pantel
3. J. Reis-Filho
4. L. Diaz

In Pulmonary and Respiratory Medicine

1. Raghu Kalluri
2. K. Pantel

Citations in the corpus

• PD-1 Blockade in Tumors with Mismatch-Repair Deficiency (2015, neutral): “Declines in CEA levels preceded objective radiographic evidence of treatment benefit by several months; perhaps other biomarkers, such as circulating tumor DNA, would also be beneficial as surrogate markers of early response.(51-53) Second, our results suggest that the evaluation of tumor genomes ca”
• Integrated digital error suppression for improved detection of circulating tumor DNA (2016, neutral): “(2) np g © 2 01 6 N at ur e A m er ic a, In c.”
• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. (2022, background): “Due to the short half-life of ctDNA 12 and the possibility of non-invasive repeated sampling, blood ctDNA allows real-time monitoring of disease during therapy.”
• The Next-Generation Sequencing Revolution and Its Impact on Genomics (2013, neutral): “…changes with high sensitivity poses an interesting and potentially powerful disease-monitoring capability that likely would complement imaging modalities such as CT or MRI but at much lower cost and with lower associated morbidities (Diehl et al., 2005; Diehl et al., 2008; Swisher et al., 2005).”
• Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “Moreover, ctDNA levels in the plasma vary subject to tumor load, tumor stage, and therapeutic response [91].”
• Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA (2015, background): “5 hours in circulation due to rapid hepatic and renal clearance, ctDNA reflects a realtime genomic signature of the tumor versus NGS of archival tissues which may only reflect the cancer’s status at an earlier static time point [20,21].”
• Systems Biology of Cancer Metastasis (2019, background): “…expression of certain genes(Zheng et al., 2007), methylation patterns(Barault et al., 2018; Garrigou et al., 2016) or mutations(Board et al., 2010; Diehl et al., 2008) in circulating tumor DNA, the types of circulating tumor and immune cells(Ilie et al., 2012), and detected from blood or other…”
• Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. (2018, background): “the somatic variant allele fraction or detected somatic variant events per unit of plasma.(64,65) Because the formermethod is a ratio of somatic”
• The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020. (2020, background): “This concept was further advanced by developing BEAMing (8) and its potential highlighted with some of the earliest circulating tumor DNA (ctDNA) measurement in cancer patients (9).”